Beyond Biotech - the podcast from Labiotech Johnson & Johnson’s hematology portfolio: breakthroughs to watch
Dec 19, 2025
In this discussion, Ester in t'Groen, the Medical Affairs Head for Hematology at Johnson & Johnson, shares her expertise following the ASH Annual Meeting. She dives into their robust hematology portfolio, highlighting the evolution of daratumumab and the exciting results of the MajesTEC-3 trial. Ester discusses how CAR-T therapies are transforming patient care and presents compelling real-world evidence that shows significant benefits for blood cancer patients. She also previews what's on the horizon for 2026, including next-gen therapies and combination strategies.
AI Snips
Chapters
Transcript
Episode notes
Real-World Data Validates Trial Results
- Real-world evidence confirmed clinical trial benefits for patients outside controlled settings.
- That data helps physicians understand treatment impact for everyday patients.
Focus Where You Can Lead
- Focus resources on a few disease areas to maximize impact and expertise.
- J&J concentrates on oncology, immunology, neuroscience, and cardiopulmonary conditions.
Daratumumab Shifted Treatment Earlier
- Daratumumab evolved from late-line to multiple frontline approvals over a decade.
- Early use transformed multiple myeloma prognosis, extending median PFS dramatically.